Race Oncology (ASX:RAC) 2024 Annual General Meeting

(1:28:47)

Race Oncology on RC220 ethics, 2024 milestones and 2025 outlook

(6:5)

Race Oncology Investor Briefing

(1:31:49)

Interview with Dr Ving Lee - \

(10:59)

Race Oncology advances RNA epigenetics with FTO drug discovery at Monash

(4:52)

Sharewise Webinar with Race Oncology CEO Daniel Tillett

(33:20)

Interview with Dr Ron Hargreaves - \

(4:59)

Race Oncology (ASX: RAC) reveals breakthrough chemotherapy heart protection discovery for Zantrene®

(6:42)

Race Oncology featured on NBN news

(1:56)

Race Oncology AGM 2021 Share Purchase Plan Explained

(5:17)

Race CEO Daniel Tillett Joins Hot Copper webinar to discuss bringing medical developments to market

(8:11)

Race Oncology completes GLP studies for RC220 bisantrene; closer to human trials

(5:15)

Investor Presentation

(38:32)

Race Oncology AGM 2020

(41:56)

Race Oncology ASX Small and Mid Cap Conference

(13:32)

Race Oncology starts world-first cancer trial to treat rare form of leukaemia

(8:22)

Race Oncology (ASX:RAC) CEO, Phillip Lynch presents at V-Con

(12:59)

Race Oncology (ASX: RAC) Investor briefing - May 2021

(54:51)

Race Oncology at Gold Coast Investor Showcase 2022

(15:14)